This year, the predicted flurry of merger and acquisition (M&A) activity might not have materialised. However, as we near the end of the year, there were some big moves.
Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare i
Artificial intelligence (AI) has now moved beyond its initial hype towards becoming a key part of the pharma industry – with many companies looking to partner with AI drug discovery start-u
Johnson & Johnson is rolling out its ‘no strings attached’ innovation incubator project JLABS to Europe – and has chosen a site in Belgium with a link to the company’s history.
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas